ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

mavorixafor

Also written as “Mavorixafor”, “X4P-001” and “AMD11070”.

Its studies are mostly in Neutropenia · Carcinoma, Renal Cell · Hepatic Insufficiency · Waldenstrom Macroglobulinemia · Triple Negative Breast Neoplasms, led by 3 companies.

Drug pageMavorixafor: every studyAll 16 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jun 19, 201914 company-led studies, 2 open or runningNext primary completion: Sep 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
X4 Pharmaceuticalsits history only122 open or runningphase 3since Jun 19, 2019Jan 20, 2016Sep 2027phase 3 · NCT06056297
Abbisko Cayman10 open or runningphase 2since Sep 25, 2021Sep 25, 2021none ahead
Sanofiits history only10 open or runningphase 1since Aug 3, 2006Aug 3, 2006none ahead

Also a collaborator on its studies: Covance.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Abbisko Cayman only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 9, 2017Named mavorixaforINNProposed as its International Nonproprietary Name in WHO's List 118 · before, X4P-001, AMD11070
  2. Sep 25, 2021First study: phase 2 study in Triple Negative Breast NeoplasmsFirst studyNCT05103917 · 24 enrolled · China

TargetBeta

CXCR4 →read by rule
“An orally bioavailable inhibitor of C-X-C chemokine receptor type 4 (CXCR4), ”NCIt, by rule
“C-X-C chemokine receptor type 4 antagonist”ChEMBL 37, by rule

Studies

The one study Abbisko Cayman leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05103917Triple Negative Breast Neoplasms · China2UNKNOWNNov 24, 202224

How it is read

Names in the registry

  • “Mavorixafor”, 7 entries
  • “X4P-001”, 6 entries
  • “AMD11070”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.